Kai Er (凯尔)凯尔

This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。

Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。

生产企业Manufacturer

主要成分Active Ingredients

药物知识说明

尼麦角林是一种在国家药监局注册认定的药品。该药品含有尼麦角林-eaaf21a9等成分。

该药品关联的活性成分包括:尼麦角林Nimai Jiaolin。这些成分信息来自国家药监局数据库。

该药品标注的生产企业为:海南通用三洋药业有限公司Chinese legal name: 海南通用三洋药业有限公司。

您可以探索含有相同成分的其他药品:尼麦角林-eaaf21a9成分药品。

本页面内容来自国家药监局数据库,MedicineGraph在此基础上提供关系图谱和知识导航。

Medicine Knowledge

This medicine (original name: 凯尔) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).

Active ingredients associated with this product: 尼麦角林Nimai Jiaolin.

Manufacturers recorded for this product: 海南通用三洋药业有限公司Chinese legal name: 海南通用三洋药业有限公司.

Explore other medicines containing the same ingredient: 尼麦角林 productsProducts containing this recorded ingredient.

Source: MedicineGraph authoritative database. Relationships derived from registered product information.

这是什么What is this

  • 通用名/品名Recorded product name: 凯尔Recorded Chinese name: 凯尔
  • 剂型Dosage form: 胶囊剂Capsules
  • 规格Specification: 30mg*10粒30 mg × 10 capsules

本段仅展示注册/说明书已记录的身份属性,不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.

主要成分Ingredients

生产企业Manufacturer

  • 海南通用三洋药业有限公司Chinese legal name: 海南通用三洋药业有限公司

注册信息NMPA approval number

  • 批准文号NMPA approval number: 国药准字H20093499

信息来源Source and scope

国家药品监督管理局(中国)药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.

  • 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
  • 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
  • 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)

范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.

本段为已核准说明书原文摘录(非改写、非AI摘要),非正式英文标签,亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.

English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.

NMPA approval number

国药准字H20093499

Manufacturer

Chinese legal name: 海南通用三洋药业有限公司 (domestically manufactured)

Indications

English translation unavailable. The original Chinese source label remains available below.

Dosage and administration

English translation unavailable. The original Chinese source label remains available below.

Adverse reactions

English translation unavailable. The original Chinese source label remains available below.

Contraindications

English translation unavailable. The original Chinese source label remains available below.

Precautions

English translation unavailable. The original Chinese source label remains available below.

Storage

Keep sealed.

Specification

30 mg × 10 capsules

中文说明书原文Original Chinese source label

批准文号

国药准字H20093499

生产企业

海南通用三洋药业有限公司(国产)

适应症

慢性周围循环障碍,如肢体血管闭塞性疾病,雷诺氏综合症,其他末梢循环不良症状,也用于老年性耳聋,视网膜疾病等,也可用于烧伤后应激激素释放导致的侧小动静脉痉挛,血流量减少,血液高凝状态等微循环障碍。

用法用量

1. 动脉疾病:每天一粒30mg胶囊,早晨服用。 2.智力衰退和有头晕感的老年人:每早一粒30mg胶囊。 3.遵医嘱。

不良反应

可观察到下列症状出现轻度的胃痛。突然直立性血管舒张性阵热或头晕。

禁忌

本品不适用于下述情况:近期心肌梗塞、急性出血、严重的心动过缓、直立性调节功能障碍、出血倾向和对尼麦角林过敏者。

注意事项

孕妇慎用。

贮藏

密封。

规格

30mg*10粒

证据Evidence

  • 批准文号: 国药准字H20093499
  • rights: 本段为已核准说明书原文摘录(非改写、非AI摘要),非正式英文标签,亦不构成用药建议。

信息来源Source and scope

国家药品监督管理局(中国)药品注册数据。National Medical Products Administration (China) medicine-registration data.

范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.